Neogen Corporation (NEOG) Aandelenanalyse

Bedrijfsoverzicht

Neogen Corporation is a specialized manufacturer dedicated to developing and marketing products and services focused on food and animal safety within the United States and international markets. The company operates through two distinct segments, Food Safety and Animal Safety, offering diagnostic test kits and complementary products to support these critical safety domains. It operates within the Healthcare sector, specifically the Medical Devices industry, where its role involves providing essential tools for regulatory compliance and pathogen detection in agricultural and food production chains. With a market capitalization of $2.05B, an annual revenue of $870.56M, and a workforce of 2974 employees, Neogen represents a mid-to-large cap entity in the medical device space. These financial scales indicate that while the company has established significant operational infrastructure and a substantial employee base, its market valuation reflects the challenges often associated with capital-intensive medical device development and the cyclical nature of the food safety industry.

Financiële gezondheid

The company reported a revenue of $870.56M for the trailing twelve months, yet it simultaneously recorded a net income of -$608.84M, revealing a severe disconnect between top-line sales and bottom-line profitability. This massive gap between revenue and net income suggests an exceptionally volatile cost structure or the recognition of significant one-time charges, as the company is generating substantial income before interest and taxes but failing to convert that into after-tax profit. Despite the negative net income, the EBITDA stands at $81.26M, indicating that the core operational cash generation before interest and taxes remains positive, though not sufficient to offset other financial burdens. The free cash flow is reported at $19.47M, which provides a limited degree of financial flexibility for capital expenditures or debt servicing, but does not offer robust funding for aggressive expansion without external capital. The margins reflect this struggle: the gross margin is 45.2%, showing that product pricing covers variable costs effectively, but the operating margin is -1.6% and the profit margin is -69.9%, highlighting that fixed costs and interest expenses are eroding profitability to a critical degree. On the balance sheet, the company holds $159.90M in cash against $795.10M in debt, resulting in a debt-to-equity ratio of 37.82, which signifies a highly leveraged position where interest obligations are a primary driver of the negative net income. The current ratio of 3.92 indicates strong short-term liquidity, suggesting the company can easily meet its immediate obligations despite the long-term debt burden. Furthermore, the return on equity is -25.6% and the return on assets is -0.6%, metrics that clearly demonstrate management's current inability to generate returns on the capital invested by shareholders or deployed in assets.

Waarderingsbeoordeling

The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the negative earnings, while the forward P/E is 31.75. The absence of a trailing P/E and the existence of a high forward P/E imply that the market is pricing in a significant turnaround in earnings expectations for the coming year, assuming profitability will be restored soon. The price-to-book ratio is 0.97, which indicates that the stock is currently trading at approximately 97% of its book value, suggesting the market does not assign a significant premium to the company's intangible assets or future growth potential at this moment. Alternative valuation multiples provide further context, with a price-to-sales ratio of 2.36 and an EV/EBITDA of 33.05, suggesting that despite the losses, investors are willing to pay a multiple of sales that is relatively high for a company in a downturn, driven by the strong EBITDA generation. The stock's recent trading range spans from a 52-week low of $4.32 to a 52-week high of $11.43, providing a benchmark for price volatility and historical performance levels. The beta value of 1.97 indicates that the stock is nearly twice as volatile as the broader market, meaning price swings will be significantly amplified by general market movements.

Growth & Income

The company experienced a revenue growth of -4.4% year-over-year, while earnings growth is listed as N/A due to the current loss position. Since earnings are negative, there is no earnings growth to compare against revenue growth, but the decline in revenue combined with the massive increase in losses implies a structural deterioration in the company's financial trajectory. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash is retained to fund operations or pay down the substantial debt load rather than being distributed to shareholders. Consequently, the overall growth and income profile is characterized by negative revenue momentum and a total reliance on retained earnings and potential future profitability improvements rather than dividend income or current earnings expansion.